Buy Femilon

Femilon

What is Femilon?

Femilon is a combined oral contraceptive (COC) pill that contains ethinylestradiol (0.15 mg) and desogestrel (0.02 mg) as its active components. It is classified under women’s health medications and is prescribed in Hong Kong to prevent pregnancy and to manage certain menstrual-related conditions. The pill is taken orally and is available in a standard tablet formulation.

How Femilon Works in the Body

Femilon belongs to the class of combined oral contraceptives, which function through two complementary hormonal actions:

• Estrogenic activity (ethinylestradiol) - stabilises the endometrial lining and supports the suppression of the pituitary release of follicle-stimulating hormone (FSH).
• Progestogenic activity (desogestrel) - thickens cervical mucus, making it difficult for sperm to penetrate, and further suppresses luteinising hormone (LH) to prevent ovulation.

Together, these hormones inhibit the mid-cycle surge of LH and FSH, thereby blocking ovulation. The steady hormone levels also produce more regular withdrawal bleeding during the placebo week. Onset of contraceptive effect occurs after the first active tablet; however, backup contraception is recommended for the first seven days of use if the pill is started mid-cycle.

Conditions Treated by Femilon

Femilon is approved by the Hong Kong Department of Health for the following indications:

• Primary prevention of pregnancy in women of reproductive age who choose a hormonal method.
• Regulation of menstrual cycles, including reduction of menorrhagia and dysmenorrhoea.
• Improvement of acne and other androgen-related skin conditions, where clinically appropriate.

These uses are based on the well-established efficacy of combined oral contraceptives containing ethinylestradiol and a third-generation progestogen such as desogestrel.

Patient Suitability and Contraindications

Who Should Use Femilon?

Femilon is generally suitable for healthy, non-pregnant women who require reliable contraception and have no contraindications to estrogen or progestogen therapy. Ideal candidates are those who prefer a daily oral regimen and have no history of clotting disorders.

Absolute Contraindications

• Confirmed pregnancy
• History of or active venous or arterial thromboembolism (deep-vein thrombosis, pulmonary embolism, stroke, myocardial infarction)
• Known or suspected estrogen-dependent neoplasia (e.g., breast or endometrial cancer)
• Severe uncontrolled hypertension (≥160 mm Hg systolic or ≥100 mm Hg diastolic)
• Active liver disease or hepatic tumour
• Known hypersensitivity to any component of the tablet

Relative Contraindications

• Women aged ≥35 years who smoke any amount of cigarettes
• Migraine with aura
• Diabetes with vascular complications
• Renal impairment (requires clinical judgement)
• Use of concomitant medications that strongly induce hepatic enzymes (e.g., rifampicin, carbamazepine)

Special Populations

• Pregnancy & lactation: Contraindicated during pregnancy; breastfeeding women may use, but should discuss benefits and risks with a healthcare professional.
• Post-menopausal hormone therapy: Not indicated.
• Adolescents: Can be prescribed after appropriate counselling on adherence and risk assessment.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or mild gastrointestinal upset - usually transient.
• Breast tenderness or enlargement.
• Headache, which may be tension-type or migraine-type.
• Irregular breakthrough bleeding, especially during the first three months.
• Mood changes or mild depressive symptoms.

Serious Adverse Events

• Venous thromboembolism (VTE): Deep-vein thrombosis or pulmonary embolism; requires immediate medical attention.
• Arterial thrombosis: Stroke, myocardial infarction - rare but serious.
• Severe hypertension: Sudden elevation of blood pressure; monitor regularly.
• Liver dysfunction: Jaundice, hepatic adenoma; discontinue if liver injury suspected.

Drug Interactions

Major Interactions

• Enzyme inducers (e.g., rifampicin, phenytoin, carbamazepine, St. John’s wort) - may reduce contraceptive efficacy; supplemental non-hormonal contraception is advised.
• Antiretroviral agents (especially those affecting CYP3A4) - may lower plasma levels of ethinylestradiol.

Moderate Interactions

• Antifungals (e.g., ketoconazole, itraconazole) - may increase estrogen exposure, enhancing VTE risk.
• Antibiotics (e.g., tetracyclines, macrolides) - evidence of clinically significant interaction is limited, but consistency in pill intake is crucial.

Food and Lifestyle Interactions

• Food: Can be taken with or without meals; absorption is not significantly affected.
• Alcohol: Moderate consumption does not impair efficacy but excessive intake may increase liver strain.
• Driving/Machinery: No impairment expected; however, severe headache or dizziness warrants caution.

Patients should always disclose all prescription drugs, over-the-counter products, herbal supplements, and vitamins to their prescriber before initiating Femilon.

How to Take Femilon

• Standard regimen: One tablet daily for 21 consecutive days, followed by a 7-day pill-free interval (or placebo tablets) during which withdrawal bleeding occurs.
• Dosage strength: Each active tablet contains 0.15 mg ethinylestradiol and 0.02 mg desogestrel.
• Timing: Take the pill at the same time each day to maintain steady hormone levels; evening dosing is acceptable if it promotes adherence.
• Administration: Swallow the tablet whole with water; do not split, crush, or chew.
• Missed dose: If a tablet is missed and it has been less than 12 hours since the usual dosing time, take it immediately and continue the schedule. If more than 12 hours have passed, take the missed tablet as soon as remembered and use a backup method (e.g., condoms) for the next 7 days. Do not double up to compensate.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and breast tenderness. Seek emergency medical care; activated charcoal may be considered, but there is no specific antidote.
• Discontinuation: If stopping for medical reasons, a gradual taper is not required, but women should be counseled on alternative contraception immediately to avoid unintended pregnancy.

Monitoring and Follow-Up

Routine clinical monitoring for Femilon users includes:

• Blood pressure measurement at baseline and periodically, especially in women with hypertension risk factors.
• Assessment for signs of thromboembolism (leg swelling, chest pain, dyspnea).
• Menstrual pattern review during the first three cycles to ensure acceptable breakthrough bleeding.

Laboratory testing is not routinely required for healthy users, but liver function tests may be ordered if hepatic disease is suspected.

Storage and Handling

• Store at room temperature (15-30 °C), away from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Discard any tablets that are discolored, broken, or past the expiration date.
• In hot and humid Hong Kong climates, avoid storing the medication in a car glove compartment; a cool, dry drawer is preferable.

Medication-Specific Glossary

Combined Oral Contraceptive (COC)

A tablet that contains both an estrogen (ethinylestradiol) and a progestogen (desogestrel) to prevent ovulation and provide contraceptive protection.

Estrogenic Component

The portion of the medication (ethinylestradiol) that mimics natural estrogen, stabilising the endometrium and suppressing FSH.

Progestogenic Component

The portion (desogestrel) that imitates natural progesterone, thickening cervical mucus and inhibiting LH surge.

Thromboembolic Risk

The increased probability of blood clot formation associated with estrogen-containing contraceptives, particularly in the presence of additional risk factors.

Breakthrough Bleeding

Spotting or unscheduled uterine bleeding that may occur during the first few months of COC use as the body adapts to hormonal levels.

Medical Disclaimer

This article provides educational information about Femilon and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.